Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after initiation of Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.
Lp(a) meeting The Copenhagen General Population Study investigated the prevalence of FH based on LDL-c levels after adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares the results and possible ways to interpret these results.
In a large Danish contemporary general population study, low LDL-c due to PCSK9 genetic variation caused a lower CV mortality risk. Cancer and all-cause mortality were not altered by the gene variants.
In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.
Higher LDL-c associates with EOAD, independently of APOE E4. Novel rare genetic coding variants were found in APOB, which do not fully explain the association between high LDL-c and EOAD.
An analysis of the ASCOT-LLA trial showed similar associations of non-fasting and fasting lipid levels with CV events in the same individuals, with high concordance for ASCVD risk categorization based on non-fasting and fasting lipid levels.
EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.
EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.
A meta-analysis showed significantly elevated Lp(a) levels with statin therapy and a cell culture study demonstrated increased apo(a) production after statin treatment, which possibly contributes to the residual CV risk in subjects on statins.
A single-center prospective PCI-registry showed an independent association of high residual inflammatory risk and adverse clinical outcomes in patients undergoing PCI with LDL-c ≤70 mg/dL at baseline.
9% Of adults who experience MI before 50 years of age, have probable or definite FH. Statin therapy is often suboptimal and so are LDL-c levels at 1 year post-MI.
EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.